Home › Trials › NCT02724670
Clinical trial Recruiting at 1 site Interventional Ages 18 and up Men only

MR-based image-guided radiotherapy for prostate cancer

Official title: Single-arm Phase II Study of MR(Magnetic Resonance Imaging)-Based Image-guided Radiotherapy for Prostate Cancer

Run by University Hospital Tuebingen · NCT02724670 · Data updated 2026-11-12

This study is testing if using MRI during radiation therapy can make treatment safer and more effective for men with prostate cancer.

Quick facts

Study typeInterventional
Ages18 Years and up
SexMen only
Enrollment78 (estimated)
SponsorUniversity Hospital Tuebingen
Academic / other
Locations1 site (Tübingen)
StatusRecruiting
StartedMarch 2016
Main results expectedJune 2020
Study endsSeptember 2028
Registry record updatedSeptember 25, 2019
Trial IDNCT02724670 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include men with histologically proven prostate cancer who are eligible for curative treatment and have an ECOG performance scale of 0-2.

Probably not a fit

Patients with contraindications for MRI or those who have had previous pelvic radiotherapy or significant comorbidities may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the use of Magnetic Resonance Imaging (MRI) for image-guided radiotherapy (IGRT) in patients diagnosed with prostate cancer. It is a single-arm, phase II study focusing on the effectiveness and safety of MRI-based IGRT. The primary endpoint is to assess the incidence of grade 2 or higher gastrointestinal and genitourinary toxicity after two years of treatment. The study aims to improve treatment precision and patient outcomes in prostate cancer management.

Why it matters

Potential benefit: If successful, this approach could lead to reduced side effects and improved treatment outcomes for prostate cancer patients.

How similar studies have gone: Other studies have shown promise with MRI-based IGRT approaches, indicating potential for success in this area.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* histologically proven prostate cancer
* indication for curative treatment
* ECOG performance scale 0-2
* Informed consent

Exclusion Criteria:

* contraindications for curative treatment
* age\<18year
* previous pelvic radiotherapy or prostatic treatment like TURP (transurethral resection of prostate), HIFU (high intensity focused ultrasound)
* serious comorbidity leading to inability for IGRT (image-guided radiotherapy)
* contraindications for MRI (Magnetic Resonance Imaging)

Where it's running

  • Müller Arndt-Christian
    Tübingen, Germany     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464University Hospital Tuebingen 70
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.